Incidence and treatment approach of intraocular pressure elevation after various types of local steroids for retinal diseases
- PMID: 37432451
- PMCID: PMC10667145
- DOI: 10.1007/s00417-023-06163-5
Incidence and treatment approach of intraocular pressure elevation after various types of local steroids for retinal diseases
Abstract
Purpose: For the treatment of macular edema, in addition to the use of antivascular endothelial growth factors, steroids are also used intravitreally and sub-Tenon. Side effects include among others cataract formation and elevation of intraocular pressure (IOP). The aim of this retrospective study was to elicit the IOP elevation after administration of various steroidal medication, the time of onset, and the efficacy of the administered IOP-lowering therapies.
Methods: We included 428 eyes with a postoperative (n = 136), diabetic (n = 148), uveitic macular edema (n = 61), and macular edema after retinal vein occlusion (n = 83). These patients were treated with one or more diverse steroidal agents once or multiple times. These drugs included: triamcinolone acetonide (TMC) as intravitreal injection (TMC IVI) or sub-Tenon (TMC ST), as well as dexamethasone (DXM) and fluocinolone acetonide (FA) intravitreally. An increase of IOP of ≥ 25 mmHg was designated as pathological. A steroid response in anamnesis, the time of onset of IOP rise from the first administration, and the therapy administered were documented.
Results: Of 428 eyes, 168 eyes (39.3%) had IOP elevation up to a mean of 29.7 (SD ± 5.6) mmHg, which occurred at a median of 5.5 months. Steroids most frequently leading to rise of IOP included DXM (39.1% of all eyes receiving that drug), TMC IVI (47.6%), TMC ST combined with DXM (51.5%), DXM with FA (56.8%), and TMC IVI with DXM (57.4%). A Kaplan-Meier analysis and the Log Rank test showed a significant difference (p < 0.001). IOP rise was treated as follows: 119 conservatively (70.8%), and 21 surgically (12.5%, cyclophotocoagulation 8.3%, filtering surgery 1.8%, in 4 the steroidal drug implant was removed 2.4%), and 28 eyes received no therapy (16.7%). Sufficient IOP regulation was achieved in 82 eyes (68.9%) with topical therapy. In 37 eyes (31.1%) with persistently elevated intraocular pressure, topical therapy had to be continued over the follow-up of 20 ± 7 months.
Conclusions: IOP increases after any type of steroid application are not rare. Results of our study let us suspect that especially therapy with intravitreal dexamethasone, either as a monotherapy or in combination with another steroid, tends to increase IOP more than other steroids. Regular IOP checks are necessary after each steroid administration, with possible initiation of long-term conservative and/or surgical therapy if necessary.
Keywords: Macular edema; Ocular hypertension; Secondary ocular hypertension; Steroidal agents.
© 2023. The Author(s).
Conflict of interest statement
All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers' bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript.
Figures
![Fig. 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/10667145/bin/417_2023_6163_Fig1_HTML.gif)
![Fig. 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/10667145/bin/417_2023_6163_Fig2_HTML.gif)
![Fig. 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/10667145/bin/417_2023_6163_Fig3_HTML.gif)
![Fig. 4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/10667145/bin/417_2023_6163_Fig4_HTML.gif)
Similar articles
-
Intravitreal steroids for macular edema in diabetes.Cochrane Database Syst Rev. 2020 Nov 17;11(11):CD005656. doi: 10.1002/14651858.CD005656.pub3. Cochrane Database Syst Rev. 2020. PMID: 33206392 Free PMC article.
-
Anti-vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema.Cochrane Database Syst Rev. 2018 Apr 18;4(4):CD011599. doi: 10.1002/14651858.CD011599.pub2. Cochrane Database Syst Rev. 2018. PMID: 29669176 Free PMC article. Review.
-
Short-term safety of dexamethasone implant for treatment of macular edema due to retinal vein occlusion, in eyes with glaucoma or treated ocular hypertension.Graefes Arch Clin Exp Ophthalmol. 2017 Apr;255(4):725-732. doi: 10.1007/s00417-016-3553-1. Epub 2016 Nov 22. Graefes Arch Clin Exp Ophthalmol. 2017. PMID: 27878430
-
Intraocular pressure elevation following triamcinolone acetonide administration as related to administration routes.Jpn J Ophthalmol. 2009 Sep;53(5):519-22. doi: 10.1007/s10384-009-0692-5. Epub 2009 Oct 22. Jpn J Ophthalmol. 2009. PMID: 19847609
-
Intravitreal triamcinolone acetonide for treatment of intraocular oedematous and neovascular diseases.Acta Ophthalmol Scand. 2005 Dec;83(6):645-63. doi: 10.1111/j.1600-0420.2005.00592.x. Acta Ophthalmol Scand. 2005. PMID: 16396641 Review.
Cited by
-
Steroid-Induced Ocular Hypertension in Mice Is Differentially Reduced by Selective EP2, EP3, EP4, and IP Prostanoid Receptor Agonists.Int J Mol Sci. 2024 Mar 15;25(6):3328. doi: 10.3390/ijms25063328. Int J Mol Sci. 2024. PMID: 38542305 Free PMC article.
References
-
- Kass MA, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP, Parrish RK, 2nd, Wilson MR, Gordon MO. The ocular hypertension treatment study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:701–713. doi: 10.1001/archopht.120.6.701. - DOI - PubMed
-
- Fini ME, Schwartz SG, Gao X, Jeong S, Patel N, Itakura T, Price MO, Price FW, Jr, Varma R, Stamer WD. Steroid-induced ocular hypertension/glaucoma: Focus on pharmacogenomics and implications for precision medicine. Prog Retin Eye Res. 2017;56:58–83. doi: 10.1016/j.preteyeres.2016.09.003. - DOI - PMC - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical